Ocular Therapeutix, Inc.
OCUL
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.3B
$10.64
▲ 0.00%
P/E
-7.49
Mkt Cap
$2.3B
52-Wk Range
$6.23–$16.44
52-Week Range
$6.23 - $16.44
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 16.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary bioresorbable hydrogel platform enabling sustained ocular drug delivery
- FDA-approved commercial products generating revenue and market validation
- Strategic partnership with Regeneron providing development and commercialization support
- Differentiated intracameral and intravitreal implant technology with reduced dosing frequency
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
DEXTENZA market expansion in post-surgical inflammation and allergic conjunctivitis indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+30.4% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying OCUL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 3, 2026
Reported EPS of -$0.35 vs -$0.40 consensus (+11.5% surprise). Revenue of $13.5M vs $13.2M expected (+2.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.5%
Revenue trend · last 8Q
—
+15%
-28%
-18%
-6%
-22%
+1%
+0%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$15.4M
$17.1M
$10.7M
$13.5M
$14.5M
$13.3M
$10.8M
$13.5M
Margins · last 8Q
Gross
85.1%
Profit
-584.5%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 18, 2026
vs Industry
How OCUL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related